Atlas Trials

To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

Clinical trial NCT00226512 · WITHDRAWN

Trial details

NCT number
NCT00226512
Sponsor
Hadassah Medical Organization
Status
WITHDRAWN
Phase
Phase 3
Study type
INTERVENTIONAL
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Start date
2004-07-01
Enrollment
203

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.